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Abstract Nasopharyngeal carcinoma has very high incidence
and high mortality worldwide. MiRNA is related to the tu-
morigenesis and metastasis of a variety of tumors. In the
present study, we verify that the expression of miR-494 in
NPC tissues and NPC-derived cells was down-regulated, re-
spectively. The proliferation, colony formation, migration,
and invasion of NPC-derived cells were suppressed, while
the cell apoptosis was promoted, when miR-494 was over-
expressed in these cells. GALNT7 and CDK16 were con-
firmed to be the direct targets of miR-494. These results
suggested that miR-494 play an inhibitory role in the tumor-
igenesis of NPC.
Keywords Nasopharyngeal carcinoma . miR-494 . Tumor
suppressor . GALNT7 . CDK16
Introduction
Nasopharyngeal carcinoma (NPC) is a non-lymphomatous,
squamous cell malignancy arising from the epithelial cells of
the nasopharynx [1]. Some epidemiological reports about
NPC revealed its extremely unbalanced endemic distribution,
with the highest morbidity in South China [2]. The standard
treatment is radiotherapy for early-stage NPC and chemora-
diotherapy for advanced NPC around the world at the present
time [3]. Since NPC is highly sensitive to radiation, the most
common and effective treatment to NPC patients is primarily
based on radiotherapy. Besides, concurrent adjuvant chemo-
therapy can also increase survival rates [4]. However, early
diagnosis is difficult due to the location of the tumor and the
lack of clinical manifestation. In addition, NPC is highly
invasive and metastatic. Oncemetastasis occurs, the prognosis
of patients is poor [5–7]. Thus, it is crucial to investigate the
underlyingmechanism for NPC tumorigenesis and metastasis.
MicroRNAs (miRNAs) are endogenous noncoding small
single chain RNAs composed of ∼22 nucleotides which target
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the 3′ untranslated regions (3′-UTRs) of certain genes to regu-
late their expression [8–10]. MiRNAs have broad effect on
tumorigenesis and tumor biological processes including tumor
development, differentiation, metastasis, and chemoresistance
[11]. They may act as tumor suppressors or oncogenes to play
critical roles in carcinogenesis [12]. Recent studies have report-
ed that abnormal expression of miRNAs involved in NPC
development and progression by regulating cell growth, prolif-
eration, apoptosis, invasion, and metastasis [13–16], indicating
that miRNAs play important roles in NPC tumorigenesis. MiR-
494 is located on chromosome 14q32.31 [17]. Previous studies
revealed ectopic expression of miR-494 in liver cancer, lung
cancer, gastrointestinal cancer, brain tumor, and so on [18–21].
However, the potential role of miR-494 in NPC progression has
still not been clarified. In the present study, we examined the
expression of miR-494 in NPC specimens and NPC-derived
cells, and investigated the role of miR-494 in NPC-derived cell
lines by cell proliferation, colony formation, migration, inva-
sion, and apoptosis assays. We also identified polypeptide N-
acetylgalactosaminyltransferase 7 (GALNT7) and cyclin-
dependent kinase 16 (CDK16) as potential targets of miR-
494. Overall, we provided evidence showing that miR-494
may play an inhibitory role in the carcinogenesis of NPC.
Materials and methods
Specimens
A total of 20 fresh nasopharyngeal carcinoma specimens and
20 fresh normal nasopharyngeal tissues were obtained from
the Peking University Shenzhen Hospital and Shenzhen Peo-
ple’s Hospital (Shenzhen, Guangdong, China). All the NPC
samples were diagnosed as non-keratinizing squamous cell
nasopharyngeal carcinoma without chemotherapy or radio-
therapy before the surgery, and the fresh nasopharyngeal
tissues from healthy individuals were diagnosed without any
other medical illness. All specimens were frozen in liquid
nitrogen for further study. The clinicopathological information
of the patients is shown in Table 1. Staging was performed by
the 2003 UICC staging system. All patients were informed of
the purposes of this research and signed the written consent.
Cell culture
Human nasopharyngeal epithelial cell line (NP69) and three
NPC cell lines (6-10B, 9-4E, CNE2) were used in this study.
The 6-10B and CNE2 cells were generous gifts from Southern
Medical University (Guangzhou, Guangdong, China). The
other two cells, 9-4E and NP69, were provided by Peking
University Shenzhen Hospital. All NPC cell lines were cul-
tured in RPMI 1640 (Gibco, Carlsbad, CA, USA), with 10 %
fetal bovine serum (Gibco, Carlsbad, CA, USA), 1 %
antibiotics (100 μ/ml penicillin and 100 mg/ml streptomycin
sulfates), and 1 % glutamate (Gibco, Carlsbad, CA, USA),
and then incubated at 37 °C in a humidified chamber contain-
ing 5 % CO2.
Extraction of total RNA, reverse transcription,
and quantitative real-time polymerase chain reaction
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to
extract the total RNA from clinical specimen tissues according
to the user manual. 6-10B, 9-4E, or CNE-2 (4×105 cells/well)
was plated into six-well plates (BD Biosciences, USA) with
three replicate wells, respectively. The cells were trypsinized
to extract the total RNA by miRneasy Mini Kit (Qiagen,
Valencia, CA, USA) 24 h later. The RNA samples with 260/
280 ratios of 1.8–2.0 were used for further experiments. Total
RNA was converted into cDNA by using the miScript II RT
Kit (Qiagen, Valencia, CA, USA) or PrimeScriptTM RT re-
agent Kit (TaKaRa, Japan). The expression level of miR-494
was confirmed with the miScriptSYBR®green PCR Kit
(Qiagen, Valencia, CA, USA), and the mRNA expression
levels of GALNT7 and CDK16 were confirmed with the
SYBR® Premix Ex TaqTM II (TaKaRa, Japan), respectively,
according to the manufacturer’s instructions on the Roche
lightcycler 480 Real-Time PCR System. U6 and β-actin were
used as the endogenous control to normalize the data. Their
expression levels were shown as fold differences relative to
the U6 and β-actin, which was based on the equation relative
quantification (RQ)=2−ΔΔCt [ΔΔCt= (meanCtcancer−
meanCtcontrol)−(meanCtnormal−meanCtcontrol)] [15]. More-
over, the miR-494 forward primer was 5′-UGA AAC AUA
CAC GGG AAA CCU C-3′ and the U6 forward primer was
5′-ACG CAA ATT CGT GAA GCG TT-3′, and their reverse
primer was the universal primer supported by the
miScriptSYBR®green PCR Kit (Qiagen, Valencia, CA,
Table 1 Clinical and pathological characteristics in NPC patients
Characteristics Number of cases
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USA). The GALNT7 mRNA forward primer was 5′-GGG
ATTATT TGC CAT TGA ACG A-3′ and the reverse primer
was 5′-AGA CGG TAG ATA TGT CCA ACA C-3′, the
CDK16 mRNA forward primer was 5′-GCA CGA GGA
CTT GAA GAT GG-3′ and the reverse primer was 5′-CGC
ATA CGC ACT CTC ACT G-3′, the β-actin primer forward
primer was 5′-GGC ACC ACA CCT TCTACA ATG AG-3′
and the reverse primer was 5′-GGA TAG CAC AGC CTG
GATAGC A -3′.
Cell transfection
All cells were transfected with miR-494 mimic(5′-UGA AAC
AUA CAC GGG AAA CCU C-3′), negative control(5′-UUC
UCC GAA CGU GUC ACG UTT-3′), inhibitor(5′-GAG
GUU UCC CGU GUA UGU UUC A-3′), or inhibitor nega-
tive control(5′-CAG UAC UUU UGU GUA GUA CAA-3′)
(GenePharma, Shanghai, China) using the Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA), which were mixed
in the Opti-MEM® I Reduced Serum Medium (Gibco, Carls-
bad, CA, USA) after plating 24 h. Then, fluorescence micros-
copy and the quantitative real-time polymerase chain reaction
(qRT-PCR) were used to verify transfection efficiency.
Cell proliferation assay and colony formation assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbro-
mide assay (MTT, 5 mg/ml, Sigma-Aldrich) was used to
analyze the cell proliferation. 6-10B, 9-4E, and CNE2
(6,000 cells/well) with five replicate wells of each condition
were plated into 96-well plates. The blank control wells were
just set up with medium. Cell proliferation was assessed at 0,
24, 48, or 72 h post-transfection. Before the meterage, cells
were stained with 20 μl MTT and incubated at 37 °C in a
humidified chamber containing 5 % CO2 for 4 h. Then, the
MTT medium mixtures were discarded, and 150 μl dimethyl
sulfoxide (DMSO, Sigma, Shanghai, China) was added. After
shaking for 10 min at room temperature, the absorbance was
measured by the ELISA microplate reader (Bio-Rad,
Hercules, CA, USA) at a wavelength of 490 nm (with
630 nm as the reference wavelength).
A total of 1,000 cells from each group 24 h after transfec-
tion were cultured in the six-well plate for 10 days. Then, cells
were washed with phosphate-buffered saline (PBS). Cells
were fixed with paraformaldehyde for 25 min, stained with
0.1 % crystal violet (Sigma-Aldrich) for 25 min, and then
washed three times. The colonies were recorded and counted.
All phases were performed in triplicate.
Cell migration and invasion assay
For transwell migration assays, 1×104 6-10B, 9-4E, or CNE-2
cells were harvested 24 h post-transfection. Then they were
plated into the upper chambers (24-well insert, pore size 8 μm,
Corning) with 100 μl serum-free 1640 medium. The lower
chambers were filled with 500 μl RPMI 1640 containing 10%
fetal bovine serum. Then cells were cultured at 37 °C in a
humidified chamber containing 5 % CO2. Two days later, the
cells on the surface of the upper chamber were swapped with
cotton gently. Cells under the surface of the lower chamber
were washed with PBS, fixed with paraformaldehyde for
25 min, stained with 0.1 % crystal violet for 25 min, and then
washed three times.
For invasion assays, Matrigel (1:5, 50 μl/well, BD Biosci-
ence, San Jose, CA, USA) was added to transwell chambers in
24-well plate. The next steps were the samewith the migration
assays. Finally, migrated and invaded cells were counted by
taking photographs in three fields. All experiments were per-
formed in triplicate.
Cell scratch assay
Cell scratch assay was also used to examine the migration of
NPC cells. Around 3×105 6-10B, 9-4E, or CNE-2 cells were
seeded on 12-well plates 1 day before the transfection. The
cells were transfected when they grew to reach almost total
confluence, and a sterile 200-μl pipette tip was used to scrape
a clear line through the cell layer 6 h later. Then, the medium
was changed with serum-free 1640 medium. Migration dis-
tance was observed under the invertedmicroscope and imaged
at the time of 0, 12, and 24 h. Experiments were performed in
triplicate.
Cell apoptosis assay
For cell apoptosis analysis, 2×105 6-10B, 9-4E, or CNE-2
cells were seeded on six-well plates. The cells were incubated
at 37 °C in a humidified chamber containing 5 %CO2 for 48 h
after transfection. The cells were collected and washed twice
with pre-chilled PBS. Then they were resuspended in 1×
binding buffer and stained with Annexin V-FITC (AV, 5 μl)
and propidium iodide (PI, 3 μl) by using the annexin V-
fluorescein isothiocyanate (FITC)/PI detection kit (Invitrogen,
Carlsbad, CA, USA). Finally, flow cytometry (EPICS, Xl-4,
Beckman, CA, USA) was used to quantify the percentage of
apoptotic cells after mixed for 15 min at room temperature.
Each experiment was done at least three times.
Luciferase reporter assay
The miRNAs target sequences were inserted between the
XhoI–NotI restriction sites in the 3′-UTR of the hRluc gene
of the psiCHECKTM-2 luciferase vector (Promega, Madison,
WI, USA) to generate reporter constructs. The primer se-
quences for the 3′-UTR of GALNT7 mRNA (forward primer
5′-CCG CTC GAG ATT GTC CAC TGA CAT TTG GGA
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TTTA-3′ and reverse primer 5′-AAG GAA AAA AGC GGC
CGC CAA ACT TCC TCT GGC AGTAGT TTG T-3′) and
CDK16 mRNA (forward primer 5′-CCG CTC GAG TCA
TAC CAG CCC CCA GGA CCA CTA C-3′ and reverse
primer 5′-AAG GAA AAA AGC GGC CGC GTT CCA
AATAGG GGC TGT GTC CCT G-3′) were designed. They
contain the potential binding sites to verify the binding sites of
the miR-494. Meanwhile, G and T, and A and C were
substituted to mutate the potential binding sites (Fig. 6a, c).
All these four short fragments were cloned into
psiCHECKTM-2 luciferase vectors, respectively, and all the
constructs were verified by sequencing. They were transfected
together with miR-494 mimic, negative control, inhibitor, or
inhibitor negative control into 6-10B, 9-4E, or CNE2 cells in
three replicate wells. After 48 h, the dual luciferase assay
system (Promega, Madison, WI, USA) was used to detect
the luciferase activity according to the manufacturer’s instruc-
tions. Normalized data were analyzed by the quotient of
Renilla/firefly luciferase activities. The experiments were re-
peated at least three times.
Western blotting
A total of 3×105 6-10B, 9-4E, or CNE-2 cells were seeded on
six-well plates and then transfected as mentioned above. Ra-
dio immunoprecipitation assay (RIPA) lysis buffer (Sigma,
USA) was used to lyse the cells 48 h later. A total of 20 μg
protein sample was loaded in each well and separated with
10 % sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE). The proteins were then electroblotted onto
polyvinylidene difluoride (PVDF) membrane (Millipore, Bil-
lerica, MA, USA) with wet blotting. After being blocked in
blocking buffer (1× Tris-buffered saline (TBS), 0.1 % Tween-
20, and 5 % nonfat milk) for 2 h at room temperature, the
membranes were incubated with rabbit anti-GALNT7
(1:2,000, Abcam, USA), or anti-CDK16 (1:2,000,
Proteintech, China), or anti-β-actin (1:1,000, Santa, USA)
overnight at 4 °C, followed by incubation with an horseradish
peroxidase (HRP)-linked secondary antibody (1:10,000,
EarthOx, LLC, USA) for 1 h at room temperature. At last,
the Chemiluminescence Phototube-HRP kit (WBKLS0500,
Millipore) was used to visualize the immunoreactive bands.
Statistical analysis
All data were presented as the mean±standard deviation (x±
SD) from the three independent experiments. All data were
analyzed by the SPSS 19.0 statistical software (SPSS Inc.
Chicago, IL, USA). MTT data were analyzed by analysis of
variance (ANOVA). The clinicopathological information of
the patients was analyzed by chi-square (χ2) test, while other
data were determined by Student’s t test. Furthermore, p<0.05
was considered to be statistically significant.
Results
MiR-494 expression is down-regulated in human NPC
clinical specimens and NPC-derived cells
The expression of miR-494was examined in 20 freshly frozen
NPC clinical specimens and 20 normal nasopharyngeal
Fig. 1 The expression of miR-494 in NPC tissues and NPC-derived
cells. a MiR-494 is down-regulated in NPC qRT-PCR of miR-494 ex-
pression relative to U6 expression in 20 NPC tumor samples compared to
20 normal nasopharyngeal epithelial tissues. b qRT-PCR showed that
miR-494 was down-regulated in 6-10B, 9-4E, and CNE2 cells compared
with NP69 cell. 2−ΔΔCT method was used to analyze the data, and the
data are presented as mean±SD (*p<0.05, **p<0.001)
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epithelial tissues. As shown in Fig. 1a, the expression of miR-
494 was significantly down-regulated in NPC tissues com-
pared with that in normal nasopharyngeal epithelial tissues.
We also analyzed the expression of miR-494 in three NPC
cell lines (6-10B, 9-4E, and CNE2) and normal nasopharyn-
geal epithelial cell line (NP69). As shown in Fig. 1b, miR-494
expression was lower in 6-10B, 9-4E, and CNE2 cells (p=
0.001, p=0.001, p=0.001) than that in NP69 cells, which is in
accordance with the expression pattern of miR-494 in clinical
tissues.
Validation of cell transfection efficiency
As shown in Fig. 2a, the transfection efficiency was more than
90 % when the cells were transfected with fluorescence-
conjugated miRNA. qRT-PCR was used to verify the trans-
fection effect and revealed that miR-494 was over-expressed
obviously after transfection with miR-494 mimic in 6-10B
(p<0.001), 9-4E (p=0.045), and CNE2 (p=0.001) cells, and
decreased after transfection with miR-494 inhibitor in 6-10B
(p=0.019), 9-4E (p=0.005), and CNE2 (p=0.010) cells
(Fig. 2b).
MiR-494 restrains the NPC cells proliferation and colony
formation
MTT assay and colony formation assay were performed
to observe whether differential expression of miR-494
affected the proliferation ability of NPC cells. MTT
assay showed that the cell proliferation was significantly
Fig. 2 Validation of cell transfection efficiency. a Phase-contrast and
green fluorescence images were taken from the same field. b The relative
expression levels of miR-494 in 6-10B, 9-4E, and CNE2 cells transfected
with miR-494 mimic, negative control, miR-494 inhibitor, or inhibitor
negative control. Data are presented as mean±SD (*p<0.05, **p<0.001)
Fig. 3 MiR-494 restrains the NPC cells proliferation and colony forma-
tion. a Cell growth was measured by MTT assay at different time
intervals. b Representative images of colony formation assay of miR-
494-transfected 6-10B, 9-4E, and CNE2 cells. Data are presented as
mean±SD (*p<0.05, **p<0.001)
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Fig. 4 MiR-494 suppresses NPC cells migration and invasion. a, b
Transwell migration assays and cell scratch assay were used to examine
the 6-10B, 9-4E, and CNE2 cells’ migration after transfection with miR-
494 mimic, negative control, miR-494 inhibitor, or inhibitor negative
control. c Transwell invasion assays showed the cells’ invasion after
transfection with miR-494 mimic, negative control, miR-494 inhibitor,
or inhibitor negative control. Data are presented as mean±SD (*p<0.05,
**p<0.001)
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decreased by 7.9 % (24 h), 15.9 % (48 h), and 25.0 %
(72 h) in 6-10B cells (p<0.001); 11.8 % (24 h), 16.2 %
(48 h), and 15.9 % (72 h) in 9-4E cells (p=0.048); and
10.1 % (24 h), 15.7 % (48 h), and 23.5 % (72 h) in
CNE2 cells (p<0.001), respectively, with miR-494 mimic
transfection compared with that with negative control
transfection. Furthermore, the cells transfected with
miR-494 inhibitor revealed obvious promotion of cell
growth compared with those transfected with inhibitor
negative control. The promotion rates of cell prolifera-
tion were 14.3 % (24 h), 20.0 % (48 h), and 18.0 %
(72 h) in 6-10B cells (p=0.006); 11.4 % (24 h), 16.4 %
(48 h), and 20.1 % (72 h) in 9-4E cells (p<0.001); and
20.9 % (24 h), 34.2 % (48 h), and 31.1 % (72 h) in
CNE2 cells (p=0.001) (Fig. 3a).
In addition, NPC cells transfected with miR-494 mim-
ic displayed fewer and smaller colonies than those
transfected with negative control, and the inhibition rates
of colony formation were 59.1 % (p=0.017) in 6-10B
cells, 59.3 % (p=0.013) in 9-4E cells, and 51.1 % (p=
0.012) in CNE2 cells. On the other hand, the cells
transfected with miR-494 inhibitor showed more and
larger colonies than those transfected with inhibitor neg-
ative control, and the promotion rates of colony forma-
tion significantly increased by 145.4 % (p<0.001),
57.6 % (p=0.012), and 93.3 % (p=0.003) in 6-10B, 9-
4E, and CNE2 cells, respectively (Fig. 3b).
MiR-494 suppresses NPC cells migration and invasion
The cell migration was examined by transwell migration assay
and cell scratch assay. Transwell migration assay showed that
the migration ability of cells transfected with miR-494 mimic
was reduced significantly compared with those transfected
with negative control. The number of migrated cells was
decreased by 40.5 % (p=0.005) in 6-10B cells, 59.5 % (p=
0.009) in 9-4E cells, and 26.3 % (p=0.006) in CNE2 cells. At
the same time, cell migration ability was obviously increased
after transfected with miR-494 inhibitor compared with that
transfected inhibitor negative control. The number of migrated
cells was increased by 145.9 % (p<0.001) in 6-10B cells,
128.3 % (p<0.001) in 9-4E cells, and 135.8 % (p=0.003) in
CNE2 cells (Fig. 4a).
The same effect appeared in the cell scratch assay. The
inhibition rates of migration were 41.2 % for 6-10B cells
(p<0.001), 43.6 % for 9-4E cells (p=0.042), and 39.9 % for
CNE2 cells (p=0.004). The migration ability, meanwhile, was
stronger in cells transfected with miR-494 inhibitor than those
transfected with inhibitor negative control. The increase of
migration were 121.7 % for 6-10B cells (p=0.004), 58.2% for
9-4E cells (p=0.004), and 64.8 % for CNE2 cells (p=0.031)
(Fig. 4b).
Transwell invasion assay also demonstrated that the inva-
sion ability was extremely weaker in cells transfected with
miR-494 mimic than those transfected with negative control
Fig. 5 Effects of miR-494 on the apoptosis in NPC cells. The apoptosis
rates were performed by the flow cytometry analysis after 6-10B, 9-4E,
and CNE2 cells were transfected with miR-494 mimic, negative control,
miR-494 inhibitor, or inhibitor negative control. Data are presented as
mean±SD (*p<0.05, **p<0.001)
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and was also stronger in cells transfected with miR-494 inhib-
itor than those transfected with inhibitor negative control. The
number of invaded cells was decreased by 44.3 % (p<0.001)
in 6-10B cells, 62.8 % (p=0.029) in 9-4E cells, and 62.8 %
(p=0.013) in CNE2 cells after transfection with miR-494
mimic. In contrast, the number of invaded cells was increased
by 209.1 % (p=0.001) in 6-10B cells, 71.8 % (p<0.001) in 9-
4E cells, and 110.6 % (p=0.049) in CNE2 cells after transfec-
tion with miR-494 inhibitor (Fig. 4c).
Effects of miR-494 on the apoptosis in NPC cells
To investigate the effect of miR-494 on the apoptosis of NPC
cells, flow cytometry was performed to detect the apoptosis
rate. Compared with the cells transfected with negative con-
trol, the cell apoptosis rate was restrained significantly in cells
transfected with miR-494 mimic, with 20.2 vs 4.1 % in 6-10B
cells (p=0.004), and 15.6 vs 6.2 % in CNE2 cells (p=0.019).
However, it was not so obvious in 9-4E cells, with the apo-
ptosis rate being 1.6 vs 1.3 % (p=0.783). We did not observe
significant change of apoptosis when the cells were
transfected with miR-494 inhibitor. The cell apoptosis rate
was 9.3 vs 9.2 % (p=0.956), 2.4 vs 3.0 % (p=0.554), and
9.7 vs 10.6 % (p=0.686) in 6-10B, 9-4E, and CNE2 cells,
respectively, when the cells were transfected with miR-494
inhibitor and inhibitor negative control (Fig. 5).
GALNT7 and CDK16 are the potential targets of miR-494
Bioinformatic analysis (miRWalk) was used to determine the
potential targets of miR-494, and two oncogenes, GALNT7
and CDK16, were selected as potential targets for further
study (Fig. 6a, c). The luciferase reporter assay validated that
the activity of the reporter containing 3′-UTR of GALNT7
was decreased when the cells were transfected with miR-494
mimic in 6-10B cells (p=0.030), 9-4E cells (p<0.001), and
CNE2 cells (p=0.026) (Fig. 6b), while that of CDK16 was
also decreased in three NPC cells (p=0.013, p=0.034, and p=
0.018, respectively) (Fig. 6d). However, the activity of these
reporters did not change when the three types of NPC cells
were transfected with miR-494 inhibitor. For further verifica-
tion of the binding sites of miR-494, the seed sequences on the
3′-URT of GALNT7 and CDK16 were mutated (Fig. 6a, c).
The activity of the reporter containing the mutated seed
Fig. 6 GALNT7 and CDK16 are two target genes of miR-494. a, c Four
fragments of GALNT7 and CDK16 3′-UTR were constructed, which
contained the wild-type (WT) potential binding sites of miR-494 and the
mutated sequence (MU). b, d The psiCHECKTM-2 luciferase constructs
containing WT or MU sequence were transfected together with miR-494
mimic, negative control, inhibitor, or inhibitor negative control into 6-
10B, 9-4E, and CNE2 cells. Luciferase activity was measured through the
dual luciferase assay system. Data are presented as mean±SD (*p<0.05,
**p<0.001)
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sequence had no obvious change when the cells were
transfected with either miR-494 mimic or miR-494 inhibitor
(Fig. 6b, d).
MiR-494 down-regulated the protein levels of GALNT7
and CDK16 in NPC
The protein expression levels of GALNT7 or CDK16 were
examined by Western blotting in 6-10B, 9-4E, and CNE2
cells. MiR-494 mimic significantly down-regulated the pro-
tein levels of GALNT7 and CDK16. However, miR-494
inhibitor did not show obvious effect on the levels of
GALNT7 and CDK6 (Fig. 7a, b).
The expression of miR-494, GALNT7, and CDK16 was
examined in 30 freshly frozen NPC clinical specimens and 20
normal nasopharyngeal epithelial tissues. Their expression
pattern showed that the levels of GALNT7 or CDK16 de-
creased when miR-494 expression increased, suggesting that
GALNT7 and CDK16 were indeed regulated by miR-494 in
tissue samples (Fig. 7c, d).
Discussion
MiRNAs play important roles in a variety of cancers in which
these miRNAs were up-regulated or down-regulated and
functioned as either oncogenes or tumor suppressors [22,
23]. We screened for differentially expressed miRNAs in
NPC and validated that miR-494 was dramatically down-
regulated in NPC tissues and NPC-derived cells. The low
expression of miR-494 in different cancers suggests that it
Fig. 7 MiR-494 down-regulated the expression of GALNT7 and
CDK16. a, b Western blotting showed that the function of miR-494 on
GALNT7 and CDK16 expression at protein level in 6-10B, 9-4E, or
CNE2 cells after transfection of miR-494 mimic, negative control,
inhibitor, or inhibitor negative control. Date are presented as mean±SD
(*p<0.05, **p<0.001). c, d The mRNA expression level of GALNT7
and CDK16 negatively correlated with miR-494 in 30 NPC tumor sam-
ples by qRT-PCR. 2−ΔΔCT method was used to analyze the data
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might have anticancer effects. In the present study, we exten-
sively investigated the role of miR-494 and indentified its
targets in NPC cells.
Previous studies reported that miR-494 influenced the oc-
currence and development of tumor. For instance, miR-494
was involved in the proliferation, senescence, and apoptosis of
lung cancer by targeting downstream genes [18, 19]. Shen PF
[24] identified that miR-494 was down-regulated in prostate
cancer and significantly inhibited the proliferation, metastasis,
and invasion of prostate cancer cells by regulating CXCR4
which involved in many fundamental cellular process and
cancer progression. Accordingly, our study revealed that
over-expression of mir-494 could suppress the prolifera-
tion, migration, and invasion of NPC cells and promote
apoptosis dramatically. However, in 9-4E cells, the effect
of miR-494 to promote apoptosis was not so obvious as
that in 6-10B and CNE2 cells, suggesting that the intrin-
sic characteristics of certain cell types may affect their
response to miR-494.
GALNT7 is a member of the GalNAc-transferase fam-
ily which encodes GalNAc-transferase 7. GALNT7 is
very important as a follow-up enzyme in the first step of
O-glycosylation. O-glycans’ alteration leads to certain
biological behavior by changing the connection between
cancer cells and the environment around them. The chang-
es in several cancer-associated structures of the O-glycans
can alter the characteristics participating in cancer inva-
sion and metastasis and other functions of cells [25].
GalNActransferases initiates mucin-type O-linked glyco-
sylation in the Golgi apparatus by impelling the transfer of
GalNAc to serine and threonine residues on targeting
proteins to affect the biological consequences of the cell
[26]. At the same time, GALNT7 is reported to be up-
regulated in many cancers such as laryngeal carcinoma,
cervical cancer, and pancreatic cancer [27–29]. Recently,
it is reported that suppressing the expression of GALNT7
can inhibit cell invasion and metastasis [30]. Meanwhile,
another target gene, CDK16, which belongs to the CDK2
subfamily, may take part in cell cycle regulation and play
a critical role during G1 to S phase transition. Thus,
CDK2 subfamily is frequently studied on the effect of cell
proliferation and differentiation [31, 32]. CDK16 might be
a part of cellular protein networks and multiple signal
transduction cascades by interacting with other four intra-
cellular proteins [33]. As is known, lots of cell functions
depend on signaling from the cytoskeleton to the nucleus.
CDK16 could start a kinase cascade by connecting with
CDK5 to govern cytoskeletal rearrangements essential for
neuron migration and neurite outgrowth [34]. In our study,
we validated that GALNT7 and CDK16 are direct targets
of miR-494. MiR-494 could inhibit the protein expression
of GALNT7 or CDK16, and the expression levels of miR-
494 and its targets were trans-correlated in NPC tissues.
As we have shown, the expression level of miR-494 was
prominently down-regulated in three NPC-derived cells, so
further inhibition of miR-494 may not result in more observ-
able influence on the occurrence and development in NPC,
such as the NPC-derived cells apoptosis and the target genes
interference effect. On the other hand, miR-494 belongs to the
miR-154 family which has been found containing 18 mem-
bers locating in 14q32.31 (miRBase). The members are veri-
fied as oncogenes or tumor suppressors in some tumors such
as liver cancers, gliomas, prostate cancer, and gastric cancer
[35–38]. Therefore, we thought that the other members of
miR-154 family could play similar roles in regulating target
genes by binding to the different potential sites and further
inhibition of miR-494 may not result in obvious functional
changes. Whether the other members of miR-154 family play
prominent roles in NPC and the precise function of GALNT7
and CDK16 in NPC still need to be further verified in our
future study.
Overall, our study provided evidence showing that miR-
494 might be an important regulator for NPC tumorigenesis.
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